Everolimus is a medicine used to treat certain cancers and other medical conditions related to abnormal cell growth. It belongs to a class of drugs called mTOR inhibitors (mammalian target of rapamycin inhibitors).

Here are the key details:

• Composition: The active ingredient is Everolimus, available in oral tablets or dispersible tablets, with common strengths like 2.5 mg, 5 mg, and 10 mg.

• Dosage Form: Oral tablets, taken once daily or as prescribed by a doctor, usually at the same time each day.

• Mode of Action:

  • Everolimus inhibits the mTOR pathway, which is important for cell growth, proliferation, and survival.

  • By blocking this pathway, it slows or stops the growth of cancer cells and abnormal tissue.

• Uses:

  • Certain cancers – such as advanced kidney cancer (renal cell carcinoma), breast cancer, neuroendocrine tumors, and some types of brain tumors.

  • Organ transplantation – to prevent rejection by suppressing the immune system (used under special medical guidance).

  • Tuberous sclerosis complex – to reduce certain benign tumors.

• Treatment Goal: To slow disease progression, reduce tumor growth, and improve survival or quality of life, depending on the condition.

• Side Effects:

  • Common: mouth ulcers, fatigue, diarrhea, nausea, rash, infections due to weakened immunity.

  • Less common/serious: liver or kidney problems, high blood sugar or cholesterol, pneumonitis (lung inflammation), severe infections.

• Precautions:

  • Regular blood tests are required to monitor blood counts, liver and kidney function, and lipid levels.

  • Avoid live vaccines while taking Everolimus.

  • Not recommended during pregnancy or breastfeeding.

  • Can interact with several other medications that affect liver enzymes.

  • Take at the same time each day and do not crush or chew tablets unless specified.

👉 Everolimus is a targeted therapy that works by interfering with specific pathways important for cancer cell growth, and careful monitoring is essential to manage side effects and ensure effectiveness.